Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 665 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Peripheral Primitive Neuroectodermal Tumor Clear all
Completed Phase 2 Interventional

Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas

NCT00003745
View directory record Official record
Conditions
Sarcoma
Interventions
topotecan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 27, 2026, 12:54 AM EDT
Terminated No phase listed Observational

A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes

NCT01251913
View directory record Official record
Conditions
Ependymomas, Gliomas, PNET, Pineal Tumors, PCNSL (Primary CNS Lymphoma)
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 27, 2026, 12:54 AM EDT
Completed Phase 1 Interventional

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

NCT00093353
View directory record Official record
Conditions
Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma
Interventions
cefixime, irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 27, 2026, 12:54 AM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

NCT00031915
View directory record Official record
Conditions
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Interventions
imatinib mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Park Ridge, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 27, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available

Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

NCT01492673
View directory record Official record
Conditions
Neuroblastoma, Sarcoma
Interventions
Cyclophosphamide, Topotecan, and Bevacizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Phoenix, Arizona • Denver, Colorado • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 27, 2026, 12:54 AM EDT
Completed No phase listed Observational

Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging

NCT01482741
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Lung Cancer, Neuroblastoma, Testicular Cancer
Interventions
Focus Group Sessions
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 27, 2026, 12:54 AM EDT
Terminated Phase 1 Interventional

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

NCT00054405
View directory record Official record
Conditions
Recurrent Neuroblastoma
Interventions
recombinant interleukin-12, aldesleukin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 27, 2026, 12:54 AM EDT
Completed Phase 3 Interventional

Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer

NCT00090337
View directory record Official record
Conditions
Head and Neck Cancer, Pain
Interventions
acupuncture therapy, standard follow-up care
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 27, 2026, 12:54 AM EDT
Available No phase listed Expanded access

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

NCT03015844
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma
Interventions
131-I-meta-iodobenzylguanidine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
365 Days to 29 Years
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 27, 2026, 12:54 AM EDT
Recruiting Phase 1 Interventional

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

NCT07211737
View directory record Official record
Conditions
Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions
i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 24 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 27, 2026, 12:54 AM EDT
Not yet recruiting Phase 2 Interventional

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

NCT07261241
View directory record Official record
Conditions
Neuroblastoma
Interventions
Radiation: 131I-MIBG, Dinutuximab, Vorinostat
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 27, 2026, 12:54 AM EDT
Terminated Phase 1 Interventional

HGS-ETR2 to Treat Children With Solid Tumors

NCT00428272
View directory record Official record
Conditions
Ewing's Sarcoma, Osteosarcoma, Neuroblastoma, Rhabdomyosarcoma
Interventions
Lexatumumab alone, Lexatumumab in combination, Interferon gamma 1b in combination, Gamma 1b potential expansion
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 27, 2026, 12:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics]

NCT03686566
View directory record Official record
Conditions
Neuroblastoma, Sarcoma, Pediatric Cancer
Interventions
13C-glucose, No glucose infusion
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 26 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 27, 2026, 12:54 AM EDT
Recruiting No phase listed Observational

International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARE

NCT03088020
View directory record Official record
Conditions
Congenital Central Hypoventilation Syndrome
Interventions
Not listed
Lead sponsor
Ilya Khaytin
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 27, 2026, 12:54 AM EDT
Completed Phase 1 Interventional

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT00010023
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, cisplatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2011 · Synced Oct 27, 2026, 12:54 AM EDT
Active, not recruiting Phase 2 Interventional

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

NCT03363373
View directory record Official record
Conditions
Neuroblastoma
Interventions
GM-CSF + Naxitamab
Biological
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
1 Year and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 27, 2026, 12:54 AM EDT
Completed No phase listed Observational

Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

NCT01445288
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, PNET, Ependymoma, Germinoma, Medulloblastoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month to 21 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 27, 2026, 12:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions

NCT00436696
View directory record Official record
Conditions
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
9,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
2
States / cities
Jackson, Mississippi • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 27, 2026, 12:54 AM EDT
Completed Phase 1 Interventional

Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy

NCT00048386
View directory record Official record
Conditions
Neuroblastoma
Interventions
autologous neuroblastoma vaccine
Biological
Lead sponsor
Malcolm Brenner
Other
Eligibility
Up to 64 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2012 · Synced Oct 27, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available

Therapy for Children With Advanced Stage Neuroblastoma

NCT01857934
View directory record Official record
Conditions
Neuroblastoma
Interventions
cyclophosphamide, topotecan, hu14.18K322A, peripheral blood stem cell harvest, surgical resection, cisplatin, etoposide, doxorubicin, vincristine, busulfan, melphalan, peripheral blood stem cell transplantation, natural killer cell infusion, radiation therapy, GM-CSF, G-CSF, mesna, levetiracetam, interleukin-2, Isotretinoin, CliniMACS
Drug · Biological · Procedure + 2 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 27, 2026, 12:54 AM EDT
Completed Not applicable Interventional

Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation

NCT00060021
View directory record Official record
Conditions
Cancer
Interventions
acupuncture therapy, management of therapy complications, pain therapy
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 27, 2026, 12:54 AM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

NCT07437963
View directory record Official record
Conditions
Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma
Interventions
Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Dinutuximab, Echocardiography Test, FDG-Positron Emission Tomography, Iberdomide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nuclear Radiology Imaging Procedure, Sargramostim, Topotecan
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
2
States / cities
Oakland, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 27, 2026, 12:54 AM EDT
Active, not recruiting Phase 1 Interventional

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

NCT02311621
View directory record Official record
Conditions
Neuroblastoma, Ganglioneuroblastoma
Interventions
Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Months to 26 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2038
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 27, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available

Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma

NCT00578864
View directory record Official record
Conditions
Neuroblastoma
Interventions
Protracted Oral Etoposide, Doxorubicin, IV Bolus Etoposide, Cisplatin, Cyclophosphamide, Mesna, Hematopoietic Factor, Primary tumor resection
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 27, 2026, 12:54 AM EDT